Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteoporosis requires bone-specific statins.

Masao Koida1, Ryo Fukuyama, Hiromichi Nakamuta

  • 1Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Nagaotogecho 45-1, Hirakata, Osaka, Japan 573-0101. koida@pharm.setsunan.ac.jp

Current Pharmaceutical Design
|August 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of nattokinase on the pathological conditions in streptozotocin induced diabetic rats.

Heliyon·2024
Same author

Runx2 Regulates <i>Galnt3</i> and <i>Fgf23</i> Expressions and Galnt3 Decelerates Osteoid Mineralization by Stabilizing Fgf23.

International journal of molecular sciences·2024
Same author

<i>Bcl2l1</i> Deficiency in Osteoblasts Reduces the Trabecular Bone Due to Enhanced Osteoclastogenesis Likely through Osteoblast Apoptosis.

International journal of molecular sciences·2023
Same author

Sp7 Transgenic Mice with a Markedly Impaired Lacunocanalicular Network Induced Sost and Reduced Bone Mass by Unloading.

International journal of molecular sciences·2022
Same author

Runt-related transcription factor-2 (Runx2) is required for bone matrix protein gene expression in committed osteoblasts in mice.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2021
Same author

Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass.

PLoS genetics·2020

New osteoporosis treatments are emerging, but efficacy and safety vary. While bisphosphonates are effective, statins show potential for bone building if delivered effectively to bone tissue.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Background:

  • Primary osteoporosis treatments, including bisphosphonates, offer practical effectiveness but lack genuine bone anabolic effects, especially in highly osteopenic patients.
  • Nitrogen-containing bisphosphonates are a mainstay therapy, yet their limitations necessitate exploration of novel therapeutic strategies.
  • The identification of statins as inducers of bone morphogenetic protein-2 (BMP-2) has spurred research into their bone anabolic potential.

Purpose of the Study:

  • To evaluate the current landscape of osteoporosis therapies.
  • To investigate the bone anabolic properties of statins.
  • To explore strategies for enhancing statin efficacy in bone tissue.

Main Methods:

  • Review of clinical studies on bisphosphonates and statins for osteoporosis.

Related Experiment Videos

  • Analysis of laboratory studies investigating the mechanisms of statin-induced bone formation.
  • Examination of pharmacokinetic and pharmacodynamic considerations for statin delivery to bone.

    • Main Results:

    • Bisphosphonates demonstrate practical effectiveness but lack true anabolic action.
    • Current liver-targeted statins show insufficient bone anabolic effects at conventional doses.
    • Laboratory studies are elucidating the intrinsic bone anabolic mechanisms of statins.

    Conclusions:

    • Statins possess genuine bone anabolic properties that could be therapeutically harnessed.
    • Improving statin bioavailability to bone through modified dosing or derivatization is a promising avenue.
    • Further research is needed to optimize statin-based therapies for osteoporosis treatment.